Compare BIO-TECHNE Corp (TECH) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs DENTSPLY SIRONA Inc — how do they compare? BIO-TECHNE Corp trades at $72.44 (market cap $11.36B), while DENTSPLY SIRONA Inc trades at $8.82 (market cap $1.73B). The key difference: BIO-TECHNE Corp is far larger — about 6.6× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 64 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| TECH | XRAY | |
|---|---|---|
Market Cap | $11.36B | $1.73B |
Volume | 5,390,331 | 6,198,582 |
Sector | Health | Health |
52-Week High | $72.61 | $14.68 |
52-Week Low | $43.31 | $8.52 |
Typical Hold Time | 64 Days | 72 Days |
Enterprise Value | $11.39B | $3.80B |
Dividend Yield | 0.44% | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.45, down 0.11% on the day, near its 52-week high of $72.70. The stock shows bullish technical signals with strong moving average support. Fundamentally, the company maintains solid gross margins of 65.77% but faces declining net income margins, dropping from 24.6% in 2022 to 6.01% in 2025. Recent shareholder approval of Merck KGaA's acquisition at $73 per share provides a clear near-term catalyst.
The pending acquisition offers limited upside from current levels but provides downside protection. However, declining profitability trends and elevated valuation ratios (P/E 62.46) pose risks if the deal falls through. Investors should weigh the acquisition premium against fundamental deterioration in earnings quality.
Dentsply Sirona (XRAY) trades at $8.73, near its 52-week low, with a bearish technical signal and negative profitability metrics. The company reported a Q2 2026 earnings beat but faces declining revenue and negative net income margins. Recent news highlights institutional stake increases and ongoing restructuring efforts amid a challenging dental market environment.
The outlook remains cautious due to persistent margin pressure and sales declines, though the consensus price target of $13.40 suggests potential upside. Key risks include competitive pressures and execution of the turnaround plan, while institutional buying indicates some long-term confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
